HeartWire, Michael O'Riordan Apr 7, 2005 Oral cannabinoid therapy reduces progression of atherosclerosis
Geneva, Switzerland - Treatment with low-dose -9-tetrahydrocannabinol (THC) significantly reduced atherosclerotic disease progression in mice... according to the results of a recent study. Researchers suggest that THC and other cannabinoids, which are active at CB2, the cannabinoid receptor expressed on immune cells, may be valuable in treating atherosclerosis.
"We have shown that relatively low doses of THC initiated after manifestation of...artery lesions significantly inhibit atherosclerosis progression in mice," write Dr Sabine Steffens (University Hospital, Geneva, Switzerland) and colleagues in the April 6, 2005 issue of Nature.
...Previous studies have highlighted various immunosuppressive and anti-inflammatory effects of THC, the major active component of marijuana. In support of the immunomodulatory role of cannabinoids, the CB2 receptor has been identified on several types of immune cells, including -cells, T-cells, and monocytes. The researchers hypothesized that THC could alter inflammatory processes crucial in atherosclerosis, thus limiting disease progression.